

# ONCOBIOLOGICS PIPELINE

Biosimilar Candidate	Brand Equivalent	2016 WW Sales (\$bn)	Commercial Rights	Product Characterization	Clone Selection	Lab Scale Similarity	Phase I	Phase III	Upcoming Milestones
ONS-3010 (adalimumab)	HUMIRA®	\$16.1	Worldwide (ex-Emerging Markets)						Phase 3 Trial
ONS-1045 (bevacizumab)	AVASTIN®	6.9	Worldwide (ex-Emerging Markets)						Phase 3 Trial
ONS-1050 (trastuzumab)	HERCEPTIN®	7.5	Worldwide						Phase 1 Trial
ONS-4010 (denosumab)	PROLIA®/ XGEVA®	3.2	Worldwide						Lab Scale Similarity
ONS-3040 (ustekinumab)	STELARA®	2.5	Worldwide						Phase 1 Trial 2018